n important early step in atherosclerosis is binding of apolipoprotein B-100 (apoB-100)-containing lipoproteins (VLDL, IDL, and LDL) to the proteoglycan component of the extracellular matrix of the arterial intima. 1, 2 When oxidative agents or enzymes attack the proteoglycan-bound lipoproteins, they become oxidatively modified, and when various intimal proteases or lipases hydrolyze them, they become nonoxidatively modified. Whereas oxidation of proteoglycan-bound apoB-100 -containing particles triggers their release and subsequent uptake by macrophages, the nonoxidative modifications do the opposite: they enhance the strength of particle binding to proteoglycans. 3 In addition, such nonoxidatively modified apoB-100 -containing lipoprotein particles tend to aggregate and fuse, which allows progressive extracellular accumulation of lipoprotein lipids, a key phenomenon in atherogenesis. The nonoxidative modifications can also lead to intracellular lipid accumulation and so induce foam cell formation, a hallmark of early atherogenesis. 4 Thus, local modification of apoB-100 -containing lipoproteins leads to both extra-and intracellular accumulation of lipids in the arterial intima.
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In general, the nonoxidative modifications are caused by enzymes that are hydrolytic in nature, either proteolytic or lipolytic. Indeed, the arterial intima contains many different types of hydrolytic enzymes capable of lipoprotein modification. Unfortunately, however, it is currently not known which hydrolytic enzymes of the human arterial intima are actually responsible for turning the intimal lipoproteins into atherogenic particles. Among the lipolytic enzymes potentially involved in such atherogenic conversion of lipoproteins are several members of the secretory phospholipase A 2 (sPLA 2 ) family. The hydrolytic action of these enzymes on phosphatidylcholine, the major glycerophospholipid in lipoprotein particles, leads to the generation of lysophosphatidylcholine (lysoPC) and a free fatty acid (FFA).
In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Bostrom et al 5 have examined in vivo the role of Group V sPLA 2 (sPLA 2 -V) in the context of atherogenesis. The rationale for their studies derives from previous data suggesting a role for the sPLA 2 enzymes in atherosclerosis and particularly in lipoprotein modification. An important finding pointing to a role of PLA 2 enzymes in the modification of lipoprotein particles locally in the arterial intima comes from compositional analysis of lipoproteins isolated from human atherosclerotic arteries. Thus, such isolated lipoproteins have decreased phosphatidylcholine content, 6, 7 ie, a change that points to their hydrolysis by a PLA 2 enzyme.
Of the 10-member family of sPLA 2 enzymes, the effect of Group IIa sPLA 2 (sPLA 2 -IIa) in atherosclerosis has been studied extensively, and accumulating evidence both in vivo and in vitro supports a role for this particular enzyme in atherosclerosis (reviewed by Menschikowski 8 ). However, because sPLA 2 -IIa has a relatively low hydrolytic activity toward phosphatidylcholines on lipoprotein surfaces, the pathophysiologic role of this enzyme in lipoprotein modification has been questioned.
Another structurally and functionally distinct type of PLA 2 , the lipoprotein-associated PLA 2 (Lp-PLA 2 ), has also been detected in atherosclerotic lesions. 9, 10 Lp-PLA 2 is associated mainly with plasma lipoproteins, particularly with LDL, and is carried into the intima along with LDL particles. In addition, this enzyme can be synthesized and secreted within the plaque by inflammatory cells, such as macrophages, both in early and advanced atherosclerotic lesions. 9,10 Lp-PLA 2 does not hydrolyze phospholipids on native lipoproteins, but requires oxidation of phospholipids for them to become its substrate.
The action of Lp-PLA 2 on oxidatively-modified LDL has been considered to possess both anti-and proinflammatory components. 11 Thus, by reducing the content of biologically active oxidized phospholipids in minimally modified LDL, Lp-PLA 2 blocks the ability of such LDL particles to promote binding of monocytes to endothelial cells in vitro. 12 On the other hand, recent experiments have clearly indicated that the hydrolytic products generated by Lp-PLA 2 and released from the modified LDL particles, ie, lysophospholipids and oxidized FFAs, elicit proinflammatory responses in various types of cells involved in atherosclerosis (reviewed by MacPhee et al 13 ). Moreover, because increased plasma concentration of Lp-PLA 2 is a biomarker of inflammation and denotes increased risk of acute coronary events, 13 evidence favoring a proatherogenic role for Lp-PLA 2 is accumulating from several lines of studies.
As described above, the two members of the sPLA 2 family, sPLA 2 -IIa and Lp-PLA 2 , are able to hydrolyze native LDL particles only poorly, or not at all. In contrast, sPLA 2 -V has been shown to efficiently hydrolyze native LDL. 14, 15 Most importantly, sPLA 2 -V is able to hydrolyze lipoproteins in complete serum, 15 a finding indicative of the absence of natural inhibitors of the enzyme in serum, and also suggesting their absence in interstitial fluids, such as the intimal fluid, which are derivatives of blood plasma. Thus, the enzyme may also be able to act on lipoproteins in the arterial intima.
Importantly, sPLA 2 -V has been detected in atherosclerotic lesions, but until now, direct evidence for the contribution of the enzyme in atherogenesis has not been available. In the current issue, Bostrom et al 5 in their gain-of-function and loss-of-function studies in mice show that increased expression of sPLA 2 -V in bone marrow-derived cells increased atherosclerosis, whereas deficiency of PLA 2 -V in such cells reduced atherosclerosis. The activity of PLA 2 in the plasma of the variously treated mice did not change, an observation strongly supporting the idea that increased lipid deposition in mice overexpressing sPLA 2 -V was indeed attributable to the lipolytic activity of the enzyme within the arterial intima, the actual site of progressive lipoprotein accumulation. As discussed above, the likely substrates for sPLA 2 enzymes in the arterial intima are the phosphatidylcholine molecules of the retained apoB-100 -containing lipoprotein particles. This assertion is supported by the in vitro findings showing that sPLA 2 -V can avidly hydrolyze the phosphatidylcholines on lipoprotein surfaces. 14, 15 Moreover, as the enzyme binds with high affinity to proteoglycans, it has the potential to hydrolyze lipoproteins retained within the proteoglycan meshwork. 15 Binding of sPLA 2 -V to proteoglycans has been shown to actually enhance its lipolytic activity toward lipoproteins, 15 so rendering it an even better candidate responsible for lipoprotein hydrolysis in the proteoglycan-rich layer of the arterial intima. Thus, we can conclude that optimal conditions appear to prevail in the arterial intima for this particular member of the family of sPLA 2 enzymes.
Hydrolysis of lipoproteins in the arterial intima by sPLA 2 -V can potentially contribute to atherosclerosis by various mechanisms, and these options are depicted schematically in the Figure. 16 ). Second, hydrolysis of the apoB-100 -containing lipoproteins (VLDL, IDL, and LDL) by sPLA 2 can lead to their aggregation and fusion. 17 Once the phosphatidylcholine molecules on the lipoprotein surface are hydrolyzed, the lipoprotein particles become more susceptible to other types of modifications, such as oxidation 18 or hydrolysis by secretory sphingomyelinase. 19 Third, sPLA 2 -treatment enhances the binding of LDL to proteoglycans, and this may involve at least two mechanisms. Flood et al 20 have shown that sPLA 2 -treatment induces changes in the conformation of apoB-100, which, again, promote the interaction of LDL with the negatively charged proteoglycans. This finding is consistent with earlier studies showing that the sPLA 2 -generated small and dense LDL particles bind to proteoglycans more avidly than large and buoyant LDL particles. 21 In addition, our laboratory has shown that particle aggregation further enhances the binding strength of the modified LDL particles to proteoglycans. 3 This increase can be explained by the fact that LDL aggregates contain many copies of apoB-100, and, being multivalent, have the potential to interact with proteoglycans via more ionic interactions than their nonaggregated, native-sized counterparts. Interestingly, binding of LDL to proteoglycans promotes PLA 2 -induced aggregation and fusion of LDL particles, 22 and an enhanced interaction of sPLA 2 -V-treated LDL to proteoglycans has been demonstrated by Rosengren et al. 15 In terms of atherogenesis, the full repertoire of the ApoB-100 -containing lipoproteins enter the arterial intima and become entrapped within the subendothelial proteoglycan meshwork. A subendothelially located macrophage synthesizes and secretes sPLA 2 -V, which hydrolyzes the phosphatidylcholines on the surface of the entrapped lipoproteins. The two bioactive hydrolytic products released from the lipoproteins, lysophosphatidylcholines (lysoPC) and free fatty acids (FFA), exert proinflammatory actions on various intimal cells. The PLA 2 -V-modified lipoproteins aggregate, fuse, and bind to the proteoglycans more tightly. Ultimately, the proteoglycan-bound modified lipoproteins are taken up by a macrophage, which then converts into a foam cell.
above-listed interactions between lipoproteins, sPLA 2 -V, and intimal proteogycans is likely to contribute to extracellular accumulation of lipoprotein-derived lipids. Finally, modification of LDL by sPLA 2 -V can also contribute to intracellular lipid accumulation by leading to the formation of macrophage foam cells. 14, 23 Here, a recent mechanistic insight provides an extra flavor to the story: the increased uptake of sPLA 2 -Vtreated LDL appears to depend on the increased affinity of the modified LDL to the heparan sulfate proteoglycans present on the cell surface. 23 The work of Bostrom et al 5 complements the wealth of in vitro data regarding the proatherogenic role of sPLA 2 -V and provides the first in vivo support for the local action of sPLA 2 -V in the arterial intima of an experimental animal. The presence of sPLA 2 -V in lipid-rich regions of human and mouse atherosclerotic lesions and its potent activity toward lipoproteins, particularly in the presence of proteoglycans, both point to the possibility of this enzyme being a key player in lipoprotein modification during atherogenesis. Indeed, the road ahead for novel discoveries in this important field of scientific exploration of lipolytic pathways in atherogenesis looks quite promising.
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